company background image
DVAX logo

Dynavax Technologies NasdaqGS:DVAX Rapporto sulle azioni

Ultimo prezzo

US$12.42

Cap. di mercato

US$1.6b

7D

1.7%

1Y

-8.4%

Aggiornato

24 Nov, 2024

Dati

Dati finanziari dell'azienda +

Dynavax Technologies Corporation

NasdaqGS:DVAX Rapporto sulle azioni

Cap. di mercato: US$1.6b

DVAX Panoramica delle azioni

Dynavax Technologies Corporation, azienda biofarmaceutica in fase commerciale, si concentra sullo sviluppo e la commercializzazione di vaccini negli Stati Uniti. Maggiori dettagli

DVAX analisi fondamentale
Punteggio fiocco di neve
Valutazione2/6
Crescita futura4/6
Prestazioni passate2/6
Salute finanziaria4/6
Dividendi0/6

Premi

Negoziato a 72% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 39.42% all'anno

Analisi del rischio

I margini di profitto (7.9%) sono inferiori rispetto allo scorso anno (16.9%)


Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
WarrenAI
Based on Analyst Price Targets

The HEPLISAV-B Vaccine Revolution Fuels Sales Growth And Leads Market Expansion

Key Takeaways Robust sales growth and increasing market share of HEPLISAV-B signal strong revenue potential and improved margins through economies of scale. Significant cash reserves and a share repurchase plan reflect financial health and enable strategic investments in product development and market expansion.
View narrative
US$24.60
FV
49.5% undervalued intrinsic discount
20.74%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
4 days ago author updated this narrative

Dynavax Technologies Corporation Concorrenti

MiMedx Group

NasdaqCM:MDXG

US$1.4b

ACADIA Pharmaceuticals

NasdaqGS:ACAD

US$2.7b

MannKind

NasdaqGM:MNKD

US$1.9b

Alkermes

NasdaqGS:ALKS

US$4.7b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Dynavax Technologies
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$12.42
Massimo di 52 settimaneUS$15.01
Minimo di 52 settimaneUS$9.74
Beta1.34
1Variazione di 1 mese15.97%
Variazione a 3 mesi8.95%
Variazione di 1 anno-8.41%
3Variazione a 3 anni-23.90%
Variazione a 5 anni119.82%
Variazione dall'IPO-86.79%

Notizie e aggiornamenti recenti

Dynavax Technologies: What The Stock Buyback Means, What It Doesn't

Nov 13

Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Nov 12
Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Oct 12
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Recent updates

Dynavax Technologies: What The Stock Buyback Means, What It Doesn't

Nov 13

Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Nov 12
Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Oct 12
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Dynavax Technologies: Slow And Steady Wins The Race

Sep 05

Dynavax Technologies: A Two Trick Pony Operating With A Single Trick

Aug 23

Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings

Aug 14
Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings

Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Jul 12
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

May 22
Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

May 10

Dynavax: Holding Firm Despite Its Missing Cash Cow

Mar 23

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Mar 06
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Jan 31
Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Aug 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

Jun 02
Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

May 03
We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Jan 16
Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Clover, Dynavax COVID-19 vaccine gets EU GMP certificate

Sep 20

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Sep 12
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

The Alphavaxers: Dynavax And Novavax, 2 Quarters On

Aug 22

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats

Aug 04

Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Jun 03
Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Dynavax: Evolving Endemic Situation Adds To Its Risk

May 23

Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

May 12
Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

May 10
Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

Dynavax Technologies: Full Speed Ahead

Mar 01

Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Jan 28
Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Rendimenti per gli azionisti

DVAXUS BiotechsUS Mercato
7D1.7%2.5%2.2%
1Y-8.4%16.1%31.6%

Ritorno vs Industria: DVAX ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 16.1 % nell'ultimo anno.

Rendimento vs Mercato: DVAX ha avuto una performance inferiore al mercato US che ha registrato un rendimento 31.6 % nell'ultimo anno.

Volatilità dei prezzi

Is DVAX's price volatile compared to industry and market?
DVAX volatility
DVAX Average Weekly Movement5.5%
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Prezzo delle azioni stabile: DVAX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 6% ) di DVAX è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
1996408Ryan Spencerwww.dynavax.com

Dynavax Technologies Corporation, azienda biofarmaceutica in fase commerciale, si concentra sullo sviluppo e la commercializzazione di vaccini negli Stati Uniti. Commercializza HEPLISAV-B, un vaccino contro l'epatite B per la prevenzione dell'infezione causata da tutti i sottotipi noti del virus dell'epatite B negli Stati Uniti e in Europa a partire dai 18 anni. L'azienda produce e vende anche CpG 1018, l'adiuvante utilizzato in HEPLISAV-B.

Dynavax Technologies Corporation Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Dynavax Technologies con la sua capitalizzazione di mercato?
DVAX statistiche fondamentali
Capitalizzazione di mercatoUS$1.63b
Guadagni(TTM)US$20.48m
Ricavi(TTM)US$260.81m

79.7x

Rapporto P/E

6.3x

Rapporto P/S

DVAX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
DVAX Conto economico (TTM)
RicaviUS$260.81m
Costo del fatturatoUS$98.88m
Profitto lordoUS$161.93m
Altre speseUS$141.46m
GuadagniUS$20.48m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)0.16
Margine lordo62.09%
Margine di profitto netto7.85%
Rapporto debito/patrimonio netto32.8%

Come si è comportato DVAX nel lungo periodo?

Vedi performance storica e confronto